Related Experiment Video
Updated: Jan 13, 2026

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
Genomic Aberrations of Antisense Gene Transcripts in Head and Neck Cancer
Jishi Ye1, Stacy Magdalene Abbang2, Yuen-Keng Ng3,4
1Department of Pain Management, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Antisense genes are crucial in head and neck cancer (HNC). Four specific antisense genes show clinical validation, highlighting their potential as biomarkers for HNC patient outcomes and guiding future research.
Area of Science:
- Genomics
- Molecular Biology
- Cancer Research
Background:
- Antisense genes (AS), a type of long non-coding RNA (lncRNA), are transcribed from the opposite strand of human genes.
- Dysregulated expression and genomic aberrations of AS genes are implicated in various cancers, including head and neck cancer (HNC).
- A comprehensive review of HNC-associated AS genes is needed for biomarker and drug development.
Purpose of the Study:
- To conduct a comprehensive review of genomic aberrations in antisense genes associated with HNC.
- To evaluate the clinical significance of these aberrations in relation to HNC patient prognosis, disease progression, and treatment response.
- To identify promising antisense genes for clinical biomarker development in HNC.
Main Methods:
- Systematic review of literature on genomic aberrations (mutations, copy number changes, RNA expression, SNPs) of antisense genes in HNC.
- Analysis of associations between genomic aberrations and HNC patient outcomes, including prognosis, progression, and therapy resistance.
- Cross-validation of identified antisense genes across multiple independent cohorts and research studies.
Main Results:
- Only 2.3% (52/2236) of known human antisense genes have been investigated in HNC.
- Genomic aberrations in AS genes impact HNC prognosis, progression, cell signaling, and drug/radiation resistance.
- Four antisense genes—HOXA10-AS, LEF1-AS1, MSC-AS1, and ZEB2-AS1—were clinically cross-validated and consistently linked to patient outcomes in HNC.
Conclusions:
- HOXA10-AS, LEF1-AS1, MSC-AS1, and ZEB2-AS1 are prioritized candidates for clinical biomarker development in HNC.
- Further validation of single nucleotide polymorphisms (SNPs) in AS genes across diverse ethnic groups is recommended for global HNC applications.
- This review underscores the clinical relevance of antisense genes in HNC and their potential for advancing precision medicine.
More Related Videos
Related Concept Videos
lncRNA - Long Non-coding RNAs
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
RNA Splicing
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Non-LTR Retrotransposons

